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Abstract
Aims: Genome-wide association studies have identified novel BMI/obesity associated susceptibility loci. The purpose of this
study is to determine associations with overweight, obesity, morbid obesity and/or general adiposity in a Danish
population. Moreover, we want to investigate if these loci associate with type 2 diabetes and to elucidate potential
underlying metabolic mechanisms.
Methods: 15 gene variants in 14 loci including TMEM18 (rs7561317), SH2B1 (rs7498665), KCTD15 (rs29941), NEGR1
(rs2568958), ETV5 (rs7647305), BDNF (rs4923461, rs925946), SEC16B (rs10913469), FAIM2 (rs7138803), GNPDA2 (rs10938397),
MTCH2 (rs10838738), BAT2 (rs2260000), NPC1 (rs1805081), MAF (rs1424233), and PTER (rs10508503) were genotyped in
18,014 middle-aged Danes.
Results: Five of the 15 gene variants associated with overweight, obesity and/or morbid obesity. Per allele ORs ranged from
1.15–1.20 for overweight, 1.10–1.25 for obesity, and 1.41–1.46 for morbid obesity. Five of the 15 variants moreover
associated with increased measures of adiposity. BDNF rs4923461 displayed a borderline BMI-dependent protective effect
on type 2 diabetes (0.87 (0.78–0.96, p=0.008)), whereas SH2B1 rs7498665 associated with nominally BMI-independent
increased risk of type 2 diabetes (1.16 (1.07–1.27, p=7.8610
24)).
Conclusions: Associations with overweight and/or obesity and measures of obesity were confirmed for seven out of the 15
gene variants. The obesity risk allele of BDNF rs4923461 protected against type 2 diabetes, which could suggest neuronal
and peripheral distinctive ways of actions for the protein. SH2B1 rs7498665 associated with type 2 diabetes independently
of BMI.
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Several studies have established that a genetic contribution to the
pathogenesis of obesity exists [1–3]. Since the prevalence of obesity
is increasing at alarming rates worldwide, great efforts have been
made to identify the genetic components predisposing some
individuals to accumulate more body fat. Especially searches for
disease-associated single nucleotide polymorphisms (SNPs) have
been prioritised, but without noticeable success prior to 2007 where
genome-wide association studies (GWAS) were introduced. Several
GWAS of body mass index (BMI) and/or obesity have been
performed, and the first wave resulted in the suggestion of SNPs in/
near the INSIG2 [4], FTO [5], PFKP [6], and CTNNBL1 [7] genes,
however, only SNPs in the FTO locus were convincingly replicated
in other GWAS [6,8] and independent replication studies [9–11].
At the end of the first obesity GWAS wave, SNPs near the MC4R
gene were identified, both in an independent GWAS [12] and
through meta-analysis of several GWAS [13]. These associations
have subsequently been confirmed in independent replication
studies [14,15]. At the same time, another obesity gene, PCSK1,w a s
suggested using re-sequencing of linkage peaks [16], and some
replication studies have established week associations between this
gene and obesity related measures [17,18].
In 2009, the second wave of BMI/obesity GWAS were
performed, identifying 15 novel susceptibility loci. A GWAS of
BMIand weightinalmost32,000 individuals ofprimarily European
descendant validated the associations with FTO and MC4R.
Moreover, genome-wide significant associations for variants in/
near two genes formerly suggested as biological candidate genes for
obesity, BDNF and SH2B1 were observed, together with the
identification of seven new BMI/weight loci, TMEM18, KCTD15,
NEGR1, SEC16B, ETV5, FAIM2 and BAT2 [19]. A meta-analysis of
GWAS on BMI comprising more than 32,000 individuals also
confirmed the associations of FTO and MC4R, and furthermore
identified six new loci; four of them overlapping with the other
BMI/weight GWAS; SH2B1, TMEM18, KCTD15 and NEGR1 and
two novel loci GNPDA2 and MTCH2 [20]. The last GWAS of the
second wave identified three novel loci, NPC1, MAF and PTER in
individuals with early-onset morbid adult obesity [21].
Given the hypothesis-free approach used in GWAS no obvious
candidacy could be explained for most of the suggested loci.
However, a predominance of the genes nearest the identified SNPs
were expressed in the brain, and several particularly in the
hypothalamus, suggesting putative roles in the regulation of
appetite and energy expenditure [19,20,22].
Since there in the first GWAS wave were identified six loci, but
only three FTO, MC4R and PCSK1 were confirmed in independent
GWAS or replication studies, the importance of independent
replication studies to distinguish between true associations and
‘‘winners curse’’ observations is underlined. Therefore, we attempt
to confirm reported GWAS findings of association with obesity in
Danish study samples. Furthermore, obesity is a strong risk factor
of type 2 diabetes and other key metabolic traits, and therefore, the
aim of the present study is also to elucidate whether 15 SNPs in/
near the 14 loci from the second obesity GWAS wave associate
with type 2 diabetes and other key metabolic correlates.
Results
Confirmation of associations with overweight and
obesity
The BDNF rs4923461 A-allele associated with increased risk of
overweight, with a per allele OR of 1.15 (1.07–1.24, p=2.5610
24),
and borderline with obesity with a per allele OR of 1.14 (1.05–1.23,
p=0.002) but not with morbid obesity (Table 1, Table S4). This
suggested that the effect of the allele might occur at a lower BMI,
thus stratifying at 22.5 kg/m
2 showed a higher effect size with an
allelic OR of 1.21 (1.09–1.34, p=4.0610
24) (data not shown).
Similarly, BDNF rs925946 associated with overweight, with an OR
of 1.20 (1.12–1.29, p=1.4610
27), and obesity with an OR of 1.15
(1.06–1.24, p=3.9610
24) but not with morbid obesity. According-
ly, stratifying at 22.5 kg/m
2 showed an OR of 1.27 (1.15–1.40,
p=1.8610
26) per T-allele (data not shown).
A different pattern was observed for the TMEM18 rs7561317
G-allele, which strongly associated with obesity with an OR of
1.25 (1.14–1.37, p=2.1610
26) and with morbid obesity with an
OR of 1.46 (1.17–1.82, p=8.3610
24) per allele, but not with
overweight.
Both the ETV5 rs7647305 C-allele and the GNPDA2
rs10938397 A-allele associated with increased risk of obesity with
ORs 1.18 (1.08–1.29, p=1.8610
24) (rs7647305) and 1.15 (1.07–
1.23, p=1.1610
24)) (rs10938397), but not with overweight or
morbid obesity.
Association with type 2 diabetes
Only the SH2B1 rs7498665 G-allele strongly associated with
increased risk of type 2 diabetes when adjusting for age and sex
with an allelic OR of 1.18 (1.09–1.28, p=3.0610
25) and when
additionally adjusting for BMI a nominal association sustained
with an OR of 1.16 (1.07–1.27, p=7.8610
24).
The BDNF rs4923461 A-allele showed a tendency towards a
reduced risk of type 2 diabetes, however, the association was
merely nominally, with an OR of 0.87 (0.78–0.96, p=0.008) per
allele when adjusting for BMI (Table 1, Table S4), however, when
omitting adjustments for BMI the nominally tendency disap-
peared. The contradictory risk altering patterns of obesity and type
2 diabetes could suggest an interaction between the risk allele and
BMI, however, no such interaction was found (data not shown).
Associations with anthropometric measures
The BDNF rs925946 T-allele associated significantly/borderline
with three increased measures of adiposity, BMI: 0.35 kg/m
2
(0.18–0.53, p=8.2610
25), waist circumference: 0.76 cm (0.31–
1.21, p=8.7610
24), weight 1.05 kg (0.49–1.60, p=2.4610
24)
whereas the rs4923461 A-allele only associated nominally (Table 2,
Table S5). The highest per allele effect sizes of measures of
adiposity were observed for the TMEM18 rs7561317 G-allele with
increases in BMI of 0.52 kg/m
2 (0.30–0.74, p=2.9610
26), in
waist circumference of 1.05 cm (0.50–1.61, p=1.8610
24) and in
weight of 1.46 kg (0.77–2.15, p=3.1610
25). Although the A-allele
of FAIM2 rs7138803 did not reach statistical significance in the
case-control analyses of overweight and obesity, this risk allele
strongly associated with increased measures of adiposity with per
allele effects on BMI of 0.41 kg/m
2 (0.25–0.57, p=8.2610
27), on
waist circumference of 1.06 cm (0.65–1.48, p=4.9610
27) and on
weight of 1.41 kg (0.90–1.93, p=7.6610
28) (Table 2, Table S5).
GNPDA2 rs10938397 and SEC16B rs10913469 both associated
nominally with increased BMI and waist circumference (Table 2,
Table S5).
Associations with metabolic traits
BDNF rs925949 associated borderline with elevated levels of
circulating leptin, with a 6% (3–10%, p=8.3610
24) per allele
increase (ng/ml), unadjusted for BMI (Table 3 (data only shown
for BMI adjusted effect sizes), Table S5). Furthermore, this risk
allele displayed a tendency towards increased levels of fasting
plasma glucose levels, however, associations were merely nomi-
nally (Table 4, Table S5). Nominally associations were also
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Obesity Type 2 diabetes
SNP Locus Risk allele RAF (%) ORoverweight ORobesity ORmorbid obesity
OR Without BMI
adjustment
*OR With BMI
adjustment
rs7561317 TMEM18 G 84 1.08 1.25 1.46 1.13 1.04
(0.99–1.17) (1.14–1.37) (1.17–1.82) (1.02–1.26) (0.92–1.17)
p=0.08 p=2.1 610
26 p=8.3610
24 p=0.02 p=0.52
rs7498665 SH2B1 G 42 1.01 1.06 1.17 1.18 1.16
(0.95–1.08) (0.99–1.13) (1.00–1.36) (1.09–1.28) (1.07–1.27)
p=0.74 p=0.12 p=0.05 p=3.0 610
25 p=7.8610
24
rs29941 KCTD15 G 68 1.00 1.02 1.09 0.98 0.99
(0.94–1.07) (0.95–1.10) (0.93–1.28) (0.90–1.07) (0.90–1.09)
p=0.93 p=0.60 p=0.30 p=0.64 p=0.79
rs2568958 NEGR1 A 60 1.01 1.04 1.09 1.08 1.06
(0.95–1.08) (0.97–1.11) (0.93–1.27) (1.00–1.17) (0.97–1.16)
p=0.75 p=0.28 p=0.28 p=0.05 p=0.2
rs7647305 ETV5 C 81 1.10 1.18 1.41 1.12 1.04
(1.02–1.19) (1.08–1.29) (1.15–1.74) (1.02–1.24) (0.93–1.16)
p=0.02 p=1.8 610
24 p=0.001 p=0.02 p=0.5
rs4923461 BDNF A 78 1.15 1.14 1.12 0.96 0.87
(1.07–1.24) (1.05–1.23) (0.94–1.35) (0.87–1.05) (0.78–0.96)
p=2.5 610
24 p=0.002 p=0.21 p=0.4 p=0.008
rs925946 BDNF T 31 1.20 1.15 1.16 0.97 0.91
(1.12–1.29) (1.06–1.24) (0.98–1.37) (0.89–1.06) (0.83–1.00)
p=1.4 610
27 p=3.9 610
24 p=0.08 p=0.5 p=0.06
rs10913469 SEC16B C 21 1.04 1.11 1.11 0.97 0.90
(0.96–1.12) (1.03–1.21) (0.93–1.34) (0.88–1.06) (0.81–1.00)
p=0.32 p=0.01 p=0.25 p=0.47 p=0.05
rs7138803 FAIM2 A 41 1.03 1.09 1.19 1.08 1.06
(0.97–1.10) (1.02–1.17) (1.02–1.38) (1.00–1.17) (0.97–1.15)
p=0.33 p=0.01 p=0.03 p=0.06 p=0.23
rs10938397 GNPDA2 G 41 1.09 1.15 1.20 1.06 0.99
(1.02–1.16) (1.07–1.23) (1.03–1.4) (0.97–1.14) (0.90–1.08)
p=0.01 p=1.1 610
24 p=0.02 p=0.19 p=0.79
rs10838738 MTCH2 G 35 1.00 1.01 0.99 1.04 1.03
(0.94–1.07) (0.94–1.08) (0.85–1.17) (0.96–1.13) (0.94–1.13)
p=0.91 p=0.86 p=0.94 p=0.34 p=0.49
rs2260000 BAT2 T 64 1.06 1.01 1.05 0.93 0.91
(0.99–1.14) (0.94–1.09) (0.90–1.24) (0.85–1.01) (0.83–1.00)
p=0.10 p=0.81 p=0.51 p=0.08 p=0.05
rs1805081 NPC1 A 58 1.06 1.10 1.21 1.09 1.07
(1.00–1.13) (1.03–1.18) (1.03–1.41) (1.01–1.18) (0.98–1.17)
p=0.07 p=0.005 p=0.02 p=0.03 p=0.13
rs1424233 MAF G 47 1.05 1.06 1.07 0.97 0.94
(0.99–1.12) (0.99–1.14) (0.92–1.25) (0.89–1.05) (0.86–1.02)
p=0.11 p=0.08 p=0.36 p=0.40 p=0.14
rs10508503 PTER T 8 0.94 0.99 1.07 0.93 0.91
(0.84–1.05) (0.87–1.12) (0.82–1.40) (0.81–1.07) (0.78–1.07)
p=0.29 p=0.84 p=0.61 p=0.33 p=0.26
Data are presented as odds ratios (OR) (CI 95%) and p-values. OR and p-values are specified for the additive model and adjusted for age and gender.
*Association with type 2 diabetes are additionally adjusted for BMI. RAF; risk allele frequency.
doi:10.1371/journal.pone.0023531.t001
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Measures of adiposity
SNP Locus Risk allele RAF (%) BMI (kg/m
2) Waist circumference (cm) Weight (kg) Waist-to-hip ratio
rs7561317 TMEM18 G 83 0.52 1.05 1.46 0.003
(0.30–0.74) (0.50–1.61) (0.77–2.15) (0.0002–0.006)
p=2.9 610
26 p=1.8 610
24 p=3.1610
25 p=0.04
rs7498665 SH2B1 G 41 0.08 0.23 0.24 0.001
(20.09–0.24) (20.19–0.64) (20.25–0.78) (20.001–0.003)
p=0.35 p=0.28 p=0.31 p=0.28
rs29941 KCTD15 G 68 0.16 0.29 0.53 0.0008
(20.02–0.33) (20.14–0.73) (20.01–1.07) (20.002–0.003)
p=0.08 p=0.19 p=0.06 p=0.49
rs2568958 NEGR1 A 59 0.06 0.17 0.20 0.002
(20.10–0.22) (20.24–0.58) (20.31–0.72) (20.0003–0.004)
p=0.46 p=0.42 p=0.44 p=0.09
rs7647305 ETV5 C 80 0.22 0.70 0.69 0.003
(0.01–0.42) (0.18–1.22) (0.04–1.34) (0.0005–0.006)
p=0.04 p=0.008 p=0.04 p=0.02
rs4923461 BDNF A 78 0.29 0.61 0.89 0.0007
(0.10–0.49) (0.11–1.11) (0.26–1.51) (20.002–0.003)
p=0.004 p=0.02 p=0.005 p=0.63
rs925946 BDNF T 31 0.35 0.76 1.05 0.001
(0.18–0.53) (0.31–1.21) (0.49–1.60) (20.0009–0.004)
p=8.2 610
25 p=8.7 610
24 p=2.4610
24 p=0.23
rs10913469 SEC16B C 21 0.33 0.83 0.90 0.003
(0.14–0.53) (0.33-1-33) (0.27–1.52) (0.00004–0.005)
p=9.2 610
24 p=0.001 p=0.005 p=0.05
rs7138803 FAIM2 A 40 0.41 1.06 1.41 0.003
(0.25–0.57) (0.65–1.48) (0.90–1.93) (0.001–0.005)
p=8.2 610
27 p=4.9 610
27 p=7.6610
28 p=0.005
rs10938397 GNPDA2 G 41 0.28 0.61 0.73 0.002
(0.11–0.44) (0.19–1.03) (0.21–1.26) (20.0003–0.004)
p=0.001 p=0.004 p=0.006 p=0.1
rs10838738 MTCH2 G3 5 20.04 0.007 20.12 20.0004
(20.21–0.13) (20.43–0.44) (20.66–0.42) (20.003–0.002)
p=0.66 p=0.97 p=0.66 p=0.74
rs2260000 BAT2 T 63 0.07 0.29 0.58 0.0004
(20.09–0.24) (20.14–0.71) (0.05–1.10) (20.002–0.003)
p=0.39 p=0.18 p=0.03 p=0.74
rs1805081 NPC1 A 57 0.11 0.25 0.19 0.002
(20.05–0.28) (20.17–0.66) (20.33–0.71) (20.0002–0.004)
p=0.18 p=0.25 p=0.48 p=0.08
rs1424233 MAF G 47 0.15 0.16 0.44 20.0004
(20.01–0.31) (20.25–0.58) (20.07–0.95) (20.003–0.002)
p=0.07 p=0.44 p=0.09 p=0.72
rs10508503 PTER T 9 0.07 0.06 0.33 20.002
(20.22–0.36) (20.68–0.79) (20.58–1.24) (20.006–0.002)
p=0.63 p=0.88 p=0.48 p=0.4
Data are presented as effect sizes (CI 95%) per allele and p-values. Effect sizes are given in absolute values and p-values are specified for the additive model and adjusted
for age and gender. RAF; risk allele frequency.
doi:10.1371/journal.pone.0023531.t002
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Inter99 cohort.
Fasting serum lipids (mmol/l) Fasting serum adipokines and CRP (ng/ml)
SNP Locus Triglycerides
Total
cholesterol
HDL-
cholesterol
LDL-
cholesterol Leptin Adiponectin CRP
rs7561317 TMEM18 20.005 20.02 0.001 20.04 20.003 20.0004 0.03
(20.03–0.02) (20.07–0.03) (20.02–0.02) (20.1–0.02) (20.04–0.03) (20.04–0.04) (20.03–0.09)
ap=0.67
ap=0.51
ap=0.87
ap=0.21
ap=0.87
ap=0.99
ap=0.37
p=0.23 p=1.0 p=0.16 p=0.58 p=0.01 p=0.41 p=0.02
rs7498665 SH2B1 20.01 20.01 0.008 20.01 20.01 20.02 20.04
(20.03–0.005) (20.05–0.02) (20.005–0.02) (20.06–0.03) (20.04–0.02) (20.05–0.004) (20.08–0.01)
ap=0.17
ap=0.45
ap=0.22
ap=0.67
ap=0.45
ap=0.09
ap=0.12
p=0.32 p=0.54 p=0.39 p=0.59 p=0.7 p=0.09 p=0.15
rs29941 KCTD15 0.009 0.02 0.00008 0.002 0.001 0.0005 20.02
(20.01–0.03) (20.01–0.06) (20.01–0.01) (20.03–0.07) (20.03–0.03) (20.03–0.03) (20.07–0.02)
ap=0.37
ap=0.20
ap=0.99
ap=0.50
ap=0.94
ap=0.97
ap=0.31
p=0.15 p=0.13 p=0.58 p=0.34 p=0.37 p=0.82 p=0.79
rs2568958 NEGR1 20.01 20.03 0.01 20.06 0.01 0.005 0.001
(20.03–0.005) (20.07–0.008) (20.0003–0.03) (20.1–(20.02)) (20.02–0.04) (20.02–0.03) (20.04–0.05)
ap=0.16
ap=0.13
ap=0.06
ap=0.01
ap=0.40
ap=0.75
ap=0.96
p=0.29 p=0.16 p=0.12 p=0.009 p=0.24 p=0.86 p=0.84
rs7647305 ETV5 0.01 0.03 0.008 20.03 0.01 0.01 20.02
(20.012–0.03) (20.02–0.08) (20.008–0.02) (20.09–0.03) (20.02–0.05) (20.02–0.04) (20.08–0.04)
ap=0.40
ap=0.20
ap=0.35
ap=0.31
ap=0.49
ap=0.46
ap=0.52
p=0.14 p=0.12 p=0.81 p=0.42 p=0.05 p=0.76 p=0.82
rs4923461 BDNF 20.01 20.01 0.005 20.03 20.008 0.006 0.02
(20.03–0.01) (20.06–0.03) (20.01–0.02) (20.09–0.03) (20.04–0.03) (20.03–0.04) (20.04–0.08)
ap=0.34
ap=0.57
ap=0.54
ap=0.28
ap=0.65
ap=0.73
ap=0.48
p=0.92 p=0.88 p=0.68 p=0.39 p=0.22 p=0.92 p=0.13
rs925946 BDNF 20.02 20.01 0.009 20.01 0.02 0.02 0.04
(20.04-(20.0009)) (20.05–0.03) (20.005–0.02) (20.07–0.04) (20.01–0.05) (20.01–0.05) (20.01–0.09)
ap=0.04
ap=0.53
ap=0.21
ap=0.60
ap=0.24
ap=0.18
ap=0.13
p=0.55 p=0.93 p=0.93 p=0.90 p=0.0008 p=0.52 p=0.006
rs10913469 SEC16B 0.008 0.02 0.004 20.02 20.03 0.02 0.01
(20.01–0.03) (20.03–0.06) (20.01–0.02) (20.08–0.05) (20.06–0.006) (20.02–0.05) (20.04–0.07)
ap=0.49
ap=0.42
ap=0.61
ap=0.62
ap=0.11
ap=0.36
ap=0.70
p=0.07 p=0.21 p=0.52 p=0.99 p=0.52 p=0.75 p=0.09
rs7138803 FAIM2 20.0001 20.01 20.01 20.01 0.006 0.01 20.03
(20.02–0.02) (20.05–0.03) (20.02–0.003) (20.06–0.04) (20.02–0.03) (20.04–0.02) (20.08–0.01)
ap=0.99
ap=0.56
ap=0.13
ap=0.71
ap=0.65
ap=0.37
ap=0.18
p=0.10 p=0.91 p=0.003 p=0.61 p=0.001 p=0.08 p=0.66
rs10938397 GNPDA2 20.01 0.03 0.008 0.02 20.005 0.01 0.02
(20.03–0.007) (20.01–0.06) (20.005–0.02) (20.03–0.07) (20.03–0.02) (20.02–0.04) (20.03–0.06)
ap=0.24
ap=0.17
ap=0.22
ap=0.35
ap=0.71
ap=0.37
ap=0.48
p=0.98 p=0.07 p=0.96 p=0.20 p=0.07 p=0.79 p=0.06
rs10838738 MTCH2 20.002 20.02 20.02 20.02 0.02 0.01 20.0007
(20.02–0.02) (20.06–0.02) (20.04-(20.008)) (20.07–0.04) (20.007–0.05) (20.02–0.04) (20.05–0.05)
ap=0.83
ap=0.36
ap=0.002
ap=0.54
ap=0.14
ap=0.47
ap=0.98
p=0.71 p=0.33 p=0.006 p=0.59 p=0.48 p=0.40 p=0.83
rs2260000 BAT2 0.02 0.007 20.01 0.02 20.005 20.0005 20.02
(20.002–0.03) (20.03–0.04) (20.03-(20.0005)) (20.03–0.07) (20.03–0.02) (20.03–0.03) (20.07–0.03)
ap=0.08
ap=0.71
ap=0.04
ap=0.39
ap=0.70
ap=0.98
ap=0.40
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levels of circulating leptin as well as lower levels of HDL-
cholesterol (Table 3, Table S5).
Discussion
In the second obesity GWAS wave 15 variants in/near 14 loci
were identified, and several independent studies have already
attempted replication of these findings. Here in our Danish study
population we aim to validate these associations, and to elucidate
whether some of the variants associate with other clinically relevant
phenotypes. Our analyses show the same trends towards increased
obesity risk, for all variants except rs10508503 near PTER.W e
report significant associations with overweight and/or obesity for
the risk variants in/near BDNF, TMEM18, ETV5 and GNPDA2.I n
extended follow-up analyses of anthropometric and metabolic traits
in the population-based Inter99 cohort we identified associations
with risk alleles in/near BDNF, TMEM18, GNPDA2, SEC16B and
FAIM2 when no adjustments forBMIwere made.The effect sizes in
our Danish study population were generally somewhat higher than
for the discovery study (e.g. 0.52 kg/m
2 vs. 0.26 kg/m
2 for
TMEM18 rs7561317 and 0.28 kg/m
2 vs. 0.19 kg/m
2 for GNPDA2
rs10938397 [20]), but the pattern of TMEM18 yielding the highest
effect sizes is true both in our study and the discovery studies
[19,20]. FAIM2 rs7138803 on the other hand show the second
highest effect size on BMI in our study, whereas it exerts a more
modest effect in the discovery study [19].
As obesity is a strong risk factor of type 2 diabetes we also
examined associations with risk of type 2 diabetes, and
unexpectedly established a BMI-dependent borderline association
with the BDNF rs4923461 obesity risk allele and reduced risk of type
2 diabetes. An additional association with risk of type 2 diabetes,
though increasing the risk as expected, was established for the
variant in SH2B1. This latter association was nominally indepen-
dent of BMI adjustments.
Other studies have also confirmed the associations between
quantitative measures of obesity, i.e. BMI, weight and waist
circumference, and/or the risk of obesity for variants in/near
TMEM18 [23–27], SEC16B [27], NEGR1 [24,27–29], SH2B1
[26,28,30], MTCH2 [24,28,29], GNPDA2 [25,28,30], FAIM2
[25,27,30], BDNF [25,27,29], and KCTD15 [29,30], however, no
convincing pattern exist between the verified variants in the
performed studies, which could be caused by low power for
detecting modest effect sizes, and therefore, as the number of
independent replication studies increases, a meta-analyses may be
needed to determine true positive associations. The risk of type 2
diabetes has only been addressed in two other studies, and here
association between TMEM18 [28], GNPDA2 [28,30], ETV5,
FAIM2 and SH2B1 [30] and a BMI-dependent increased risk of
type 2 diabetes have been reported. Hence, we are the first to report
a tendency towards an increased risk of type 2 diabetes independent
of BMI for SH2B1, and rs7498665 could therefore be suggested as a
type 2 diabetes variant if this association is replicated in other
independent studies. Particularly surprising from our analyses was
the finding that the obesity risk allele of BDNF (rs4923461) was
borderline associated with a reduced risk of type 2 diabetes when
adjusted for BMI. However, these divergent associations were not
explained by an interaction between the variant and BMI.
Interestingly, both SH2B1 and BDNF are obvious candidate
genes for metabolic disorders based on the biological roles of the
encoded proteins. That is, the SH2B1 adaptor protein is involved
in several signal transduction processes, including the signalling
mediated by the binding of insulin and leptin [31]. The association
with type 2 diabetes is in line with previous studies showing insulin
resistance in knockout mice [32–35]. Furthermore, a recent study
demonstrated that TgKO mice, that only express SH2B1 in the
brain and thus have loss of peripheral SH2B1, have impaired
insulin sensitivity independent of body weight [35]. However,
none of the examined measures of glucose homeostasis supported
a possible reduction in insulin sensitivity in our study.
Fasting serum lipids (mmol/l) Fasting serum adipokines and CRP (ng/ml)
SNP Locus Triglycerides
Total
cholesterol
HDL-
cholesterol
LDL-
cholesterol Leptin Adiponectin CRP
p=0.05 p=0.63 p=0.03 p=0.31 p=0.84 p=0.88 p=0.48
rs1805081 NPC1 0.01 0.04 20.0005 20.0008 0.0003 20.009 20.03
(20.007–0.03) (0.006–0.08) (20.01–0.01) (20.05–0.05) (20.03–0.03) (20.04–0.02) (20.07–0.02)
ap=0.23
ap=0.02
ap=0.94
ap=0.98
ap=0.99
ap=0.55
ap=0.26
p=0.12 p=0.02 p=0.63 p=0.74 p=0.44 p=0.43 p=0.54
rs1424233 MAF 0.02 20.02 20.01 20.03 20.01 0.004 0.002
(20.002–0.03) (20.05–0.02) (20.02–0.002) (20.08–0.02) (20.04–0.02) (20.02–0.03) (20.04–0.05)
ap=0.07
ap=0.34
ap=0.1
ap=0.28
ap=0.47
ap=0.77
ap=0.92
p=0.02 p=0.50 p=0.03 p=0.43 p=0.69 p=0.97 p=0.46
rs10508503 PTER 0.004 0.03 0.02 0.01 0.005 20.0005 20.04
(20.03–0.04) (20.04–0.09) (20.004–0.04) 20.07–0.1) (20.04–0.05) (20.05–0.05) (20.1–0.05)
ap=0.79
ap=0.38
ap=0.11
ap=0.77
ap=0.83
ap=0.99
ap=0.39
p=0.66 p=0.36 p=0.19 p=0.72 p=0.66 p=0.89 p=0.49
Data are presented as effect sizes (95% CI) per allele and p-values.
aEffect sizes are adjusted for age, sex and BMI and given as absolute values for total cholesterol and HDL-cholesterol, LDL-cholesterol, and as percentages for
triglyceride, leptin, adiponectin and CRP since these traits are logarithmically transformed. LDL-cholesterol is calculated as: ((total cholesterol – HDL-cholesterol –
triglyceride/2.2). p-values are specified for the additive model and adjusted for age, sex and BMI. P-values without
a are only adjusted for age and sex. CRP, C-reactive
protein.
doi:10.1371/journal.pone.0023531.t003
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population-based Inter99 cohort.
Measures of glucose homeostasis
SNP Locus
Fasting plasma
glucose (mmol/l)
Fasting serum
insulin (pmol/l)
HOMA-IR
(mmol/lxpmol/l)
Insulinogenic index
(pmolxpmol
21)
rs7561317 TMEM18 0.001 20.03 20.03 20.02
(20.004–0.007) (20.06-(20.005)) (20.05-(20.002)) (20.05–0.01)
ap=0.58
ap=0.02
ap=0.04
ap=0.28
p=0.06 p=0.65 p=0.42 p=0.95
rs7498665 SH2B1 0.0002 0.005 0.006 0.006
(20.004–0.004) (20.13–0.02) (20.01–0.02) (20.17–0.03)
ap=0.94
ap=0.56
ap=0.57
ap=0.62
p=0.73 p=0.34 p=0.33 p=0.50
rs29941 KCTD15 0.002 0.005 0.007 0.003
(20.002–0.006) (20.01–0.02) (20.01–0.03) (20.02–0.03)
ap=0.42
ap=0.62
ap=0.51
ap=0.80
p=0.20 p=0.20 p =0.15 p=0.61
rs2568958 NEGR1 0.003 20.02 20.01 20.02
(20.0005–0.007) (20.05–0.002) (20.03–0.007) (20.05-(20.002))
ap=0.09
ap=0.08
ap=0.21
ap=0.04
p=0.06 p=0.27 p=0.52 p=0.07
rs7647305 ETV5 0.0008 0.003 0.004 20.002
(20.004–0.006) (20.02–0.03) (20.02–0.03) (20.03–0.03)
ap=0.74
ap=0.79
ap=0.78
ap=0.89
p=0.36 p=0.24 p=0.22 p=0.72
rs4923461 BDNF 20.003 20.01 20.01 0.01
(20.007–0.002) (20.03–0.01) (20.04–0.01) (20.02–0.04)
ap=0.26
ap=0.41
ap=0.34
ap=0.38
p=0.84 p=0.50 p=0.52 p=0.13
rs925946 BDNF 0.004 20.01 20.008 20.009
(20.0002–0.008) (20.03–0.008) (20.03–0.01) (20.03–0.02)
ap=0.06
ap=0.22
ap=0.47
ap=0.48
p=0.003 p=0.40 p=0.18 p=0.87
rs10913469 SEC16B 0.001 20.02 20.02 0.009
(20.003–0.006) (20.04–0.006) (20.04–0.008) (20.02–0.04)
ap=0.60
ap=0.14
ap=0.19
ap=0.52
p=0.14 p=0.71 p=0.56 p=0.16
rs7138803 FAIM2 20.0005 20.002 20.002 0.006
(20.004–0.003) (20.02–0.02) (20.02–0.02) (20.02–0.03)
ap=0.79
ap=0.82
ap=0.82
ap=0.63
p=0.23 p=0.02 p=0.02 p=0.09
rs10938397 GNPDA2 20.001 0.006 0.004 0.01
(20.005–0.003) (20.01–0.02) (20.02–0.02) (20.01–0.04)
ap=0.51
ap=0.56
ap=0.70
ap=0.28
p=0.72 p=0.03 p=0.04 p=0.08
rs10838738 MTCH2 20.0002 20.01 20.01 20.007
(20.004–0.004) (20.03–0.007) (20.03–0.008) (20.03–0.02)
ap=0.94
ap=0.21
ap=0.22
ap=0.56
p=0.82 p=0.18 p=0.19 p=0.45
rs2260000 BAT2 20.003 0.0003 20.004 20.001
(20.007–0.0009) (20.02–0.02)
ap=0.71 (20.02–0.02)
ap=0.13
ap=0.97 (20.02–0.02)
ap=0.92
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regulation of body weight [36]. Yet, our results could suggest more
ways for action of the BDNF protein. This is also supported by two
studies of db/db mice. One where exogenous BDNF treatment
reduces blood glucose concentrations independently of the
hypophagic effect [37] and another where subcutaneous BDNF
resulted in reduced blood glucose levels in BDNF administered
mice, whereas pair-fed control mice displayed unchanged levels,
despite that plasma insulin levels were significantly reduced in both
groups [38].
Consistent with animal models, plasma BDNF levels have
previously been reported to be inversely correlated with fasting
plasma glucose among type 2 diabetes patients and to be
associated with the severity of insulin resistance [39]. This suggests
that BDNF regulates blood glucose homeostasis and insulin
sensitivity peripherally. Hence, tissue specific up-regulation of
endogenous BDNF levels in peripheral tissues could explain this
BMI-dependent protective effect on type 2 diabetes for the
reported BDNF obesity risk allele (rs4923461).
Contradictory, quantitative trait analyses show that the other risk
allele near BDNF (rs925946) associated with elevated and not
decreased fasting plasma glucose levels in our study population.
Serum leptin and the inflammatory marker CRP were also found
to be significantly elevated among rs925946 T-allele carriers in the
present study. However, these associations omitted when adjusting
for BMI and is therefore most likely mediated through the
increased body fat accumulation, rather than being the cause of it.
Different neuronal and peripheral regulatory mechanisms of
BDNF could be explained by different isoforms of the protein, and
in fact tissue specific alternative splicing has been reported for
BDNF in humans [40,41]. Furthermore, the BDNFOS gene, which
is a non-protein-coding natural antisense transcript positioned
downstream of BDNF in reverse orientation, has been suggested to
have an important role in tissue specific regulation of BDNF
expression through the formation of dsRNA duplexes [41]. In fact
both gene variants are positioned within the BDNFOS locus. Thus,
it could be hypothesized that the risk alleles could result in a
muscle specific impairment of BDNFOS transcription and splicing,
which would lead to a reduction in complementary BDNF RNAs
and consequently increase the level of BDNF. Therefore
physiological and experimental studies to illuminate the tissue
specific and functional role of BDNF and BDNFOS will be of great
interest.
Of the remaining associated obesity risk loci the potential
functional role is less obvious as little is known of the encoded
proteins. Furthermore, some of the identified risk variants are next
to additional loci, in which the risk variants may influence as well.
However, most of the identified loci are highly expressed in the
brain, particularly in the hypothalamic region, indicating roles in
appetite regulation and energy expenditure [19,20,22].
Many analyses were made in this study and some should
therefore be regarded as hypothesis-generating with confirmation
in independent studies as an important next step, but these
analyses in the population-based Inter99 cohort still contribute to
the follow-up of the reported findings of the second obesity GWAS
wave.
It should moreover be noted that individuals from the Inter99
cohort (Note S1) were included in the follow-up of the top 43
variants in the BMI GWAS performed by Thorleifsson et al.
However, since these studies were pooled with other ethnicities, we
found it necessary to elucidate whether the associations with type 2
diabetes and obesity were present in an ethnically homogeneous
study to avoid confounding by population stratification. In view of
that, little overlap is observed in associations with type 2 diabetes
suggesting that the effect of the BMI risk variants on type 2
diabetes risk is dependent on geographic origin. Moreover, we
have in the present study examined the underlying metabolic
phenotypes profoundly in order to shed light on the possible
metabolic mechanisms causing the reported associations. The
Inter99 cohort is in addition used in the replication part of the
Measures of glucose homeostasis
SNP Locus
Fasting plasma
glucose (mmol/l)
Fasting serum
insulin (pmol/l)
HOMA-IR
(mmol/lxpmol/l)
Insulinogenic index
(pmolxpmol
21)
p=0.10 p=0.53 p=0.76 p=0.31
rs1805081 NPC1 0.0008 20.01 20.01 0.01
(20.003–0.005) (20.03–0.004) (20.03–0.005) (20.009–0.04)
ap=0.70
ap=0.13
ap=0.15
ap=0.24
p=0.45 p=0.45 p=0.52 p=0.24
rs1424233 MAF 20.001 20.001 20.002 0.02
(20.005–0.003) (20.02–0.02) (20.02–0.02) (20.003–0.04)
ap=0.56
ap=0.90
ap=0.85
ap=0.09
p=0.99 p=0.41 p=0.42 p=0.04
rs10508503 PTER 20.002 0.02 0.01 20.02
(20.009–0.004) (20.02–0.05) (20.02–0.05) (20.06–0.02)
ap=0.50
ap=0.33
ap=0.48
ap=0.30
p=0.64 p=0.24 p=0.34 p=0.42
Data are presented as effect sizes (95% CI) per allele and p-values.
aEffect sizes are adjusted for age, sex and BMI and are given as percentages since the traits are logarithmically transformed, and p-values are specified for the additive
model and adjusted for age, sex and BMI. P-values without
a are only adjusted for age and sex. Homeostasis model assessment of insulin resistance (HOMA-IR) was
calculated as ((fasting plasma glucose (mmol/l)6fasting serum insulin (pmol/l))/22.5). Insulinogenic index was calculated as ((serum insulin 30 minuttes post-oral
glucose tolerance test (pmol/l) – fasting serum insulin (pmol/l)/plasma glucose 30 minuttes post-oral glucose tolerance test (mmol/l)).
doi:10.1371/journal.pone.0023531.t004
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analyses of ,125,000 individuals and independent replication in
the same number, performed by the GIANT (Genomewide
Investigation of ANThropometric measures) consortium, revealing
18 new BMI associated loci [42].
In conclusion, of the variants found to associate with obesity
and related traits in the second GWAS wave, we were able to
report association with obesity and/or measures of adiposity for
variants in/near BDNF, TMEM18, ETV5, GNPDA2, SEC16B and
FAIM2. Moreover, we found that SH2B1 rs7498665 strongly
associated with type 2 diabetes in a BMI-independent manner.
Our analyses also suggested that although rs4923461 in BDNF
increase the risk of obesity, it conversely protect against type 2
diabetes, which could be through different neuronal and
peripheral mechanisms.
Materials and Methods
Study populations
The 15 SNPs from the second obesity GWAS wave were
genotyped in 18,014 individuals ascertained from four different
study groups; 1) the Inter99 cohort, which is a population-based,
randomised, non-pharmacological intervention study of middle-
aged individuals for the prevention of ischemic heart disease
(n=6,514), conducted at the Research Centre for Prevention and
Health in Glostrup, Copenhagen (ClinicalTrials.gov ID-no:
NCT00289237) [43]; 2) the ADDITION Denmark screening
study cohort (Anglo–Danish–Dutch Study of Intensive Treatment
in People with Screen-Detected Diabetes in Primary Care)
(ClinicalTrials.gov ID-no: NCT00237548) [44], which is a
population-based, high-risk screening and intervention study for
type 2 diabetes in general practice (n=8,664); 3) a population-
based group of unrelated middle-aged individuals (n=680)
examined at Steno Diabetes Center; and 4) unrelated type 2
diabetic patients (n=2,158) sampled through the out-patient clinic
at Steno Diabetes Center. In BMI stratified case-control analyses
individuals from study group 2 with BMI,25 kg/m
2 were
excluded. Hence, in the combined study sample 3,512 were
normal weight, 7,458 were overweight, 5,044 were obese, and 340
were morbidly obese. Study groups 1 and 3 underwent a standard
75 g oral glucose tolerance test. Association with type 2 diabetes
was evaluated in the combined study sample of which 5,302 were
glucose-tolerant and 3,778 were type 2 diabetes patients.
Definitions of overweight, obesity, morbid obesity and type 2
diabetes were according to WHO criteria, i.e. 25–29.99 kg/m
2,
30–39.99 kg/m
2 and $40 kg/m
2 respectively. In analyses of
overweight individuals with BMI,25.0 kg/m
2 were compared
with individuals in the BMI range 25–29.99 kg/m
2, obesity were
analysed comparing BMI,25.0 kg/m
2 with the 30–39.99 kg/m
2
range, and finally analyses of morbid obesity were made with
individuals with BMI,25.0 kg/m
2 and individuals with
BMI$40 kg/m
2.
Of note, a total of 5,586 individuals from study group 1 and
5,450 individuals from study group 2 were included in the GWAS
performed by Thorleifsson et al. [19] (Note S1).
All study participants were Danes by self report, and informed
written consent was obtained from all individuals before
participation. The studies were approved by the regional Ethical
Committees (The Scientific Ethics Committee of the Capital
Region of Denmark for study group 1, 3 and 4 and The Scientific
Ethics Committee of the Central region of Denmark for study
group 2) and were in accordance with the principles of the
Helsinki Declaration. More details of the study groups are given in
Table S1.
Biochemical and anthropometric measures
In all four study groups weight and height were measured in
light indoor clothes and without shoes. Waist circumference (cm)
was measured in standing position midway between the iliac crest
and the lower costal margin. For evaluation of quantitative traits
all analysis are performed in the Inter99 cohort as this cohort
represents the general middle-aged Danish population and
extensive phenotypic characterisations are available in this cohort.
Blood samples were drawn after a 12-hour overnight fast. Plasma
glucose was analysed by glucose oxidase method (Granutest;
Merck, Darmstadt, Germany) and serum insulin (excluding des(31,
32) and intact proinsulin) was measured using the AutoDELFIA
insulin kit (Perkin-Elmer, Wallac, Turku, Finland). Serum
triglyceride, total cholesterol and HDL-cholesterol were deter-
mined using enzymatic colorimetric methods (GPO-PAP and
CHOD-PAP; Roche Molecular Biochemicals, Mannheim, Ger-
many). LDL-cholesterol was calculated as: ((total cholesterol –
HDL-cholesterol – triglyceride/2.2). Detection antibodies for
serum adiponectin (monomeric adiponectin (ADIPOQ)) (R&D
Systems; Minneapolis, MN), leptin (R&D Systems; Minneapolis,
MN) and C-reactive protein (CRP) (U.S. Biological; Swampscott,
MA) were conjugated with Alexa Flour 647 (Invitrogen, Carlsbad,
CA) and purified by ultrafiltration with Microcon YM-30 from
Millipore (Billerica, MA).
Genotyping
SNPs for genotyping were selected as described in Note S2. The
10 variants in TMEM18, SH2B1, KCTD15, NEGR1, SEC16B,
SFRS10, BDNF, FAIM2 and BAT2 were genotyped in study group
1 by deCODE genetics using the Centaurus platform [19]. For
study group 2–4 these 10 variants were genotyped by KBioscience
using the KasPARH SNP Genotyping method. The remaining 5
variants in GNPDA2, MTCH2, NPC1, MAF and PTER were
genotyped by KBioscience also using the KasPARH SNP
Genotyping method in all four study groups. When adjusting for
the multiple tests performed, all SNPs obeyed Hardy Weinberg
equilibrium (p.0.003). All 15 SNPs passed quality control with an
average mismatch rate of 0.17% (max. 0.97%) and an average
success rate of 97.8% (min. 96.1%).
Statistical analyses
Case-control analyses were performed using logistic regression.
Type 2 diabetes studies included the full study sample, whereas
BMI stratified case-control analyses excluded individuals from
study group 2 with BMI,25 kg/m
2 as controls , since this is a
population of high-risk individuals. General linear models were
used to test quantitative metabolic traits for differences between
genotype groups in 6,039 treatment-naı ¨ve individuals from the
population-based Inter99 cohort. All analyses were performed
assuming an additive genetic model and with adjustments for age
and sex. Additionally adjustments for BMI were introduced in
case-control studies of type 2 diabetes and in quantitative trait
analyses.
Quantitative traits that did not follow a normal distribution
were logarithmically transformed.
Statistical power in replication case-control settings was
determined using the CaTS power calculator version 0.0.2. The
lowest and the highest risk allele frequencies (RAF) of the
examined SNPs were 8% and 84%, respectively, and the mean
RAF was 50%. Using the population-based Inter99 cohort as
reference, the prevalence of overweight, obesity, morbid obesity
and type 2 diabetes in the Danish population was estimated to
39%, 17%, 1.3% and 8%, respectively. Estimated statistical power
calculations in case-control settings are presented in Table S2.
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simulations (n=5,000), where variance across genotypes was
drawn from phenotypes simulated to follow normal distribution
using empirical variances. The variance for adjustment factors,
estimated using residuals of linear models, was also included in the
model, assuming independency of genotypes. Linear models were
used both for simulating and testing data, assuming additive
models and using a significance threshold of 0.05. The estimated
statistical power for variants with a RAF of 8%, 84% and 50%
respectively, were determined and are presented in Table S3. All
analyses were performed in RGui version 2.8.0. Due to the large
amount of tests performed in the present study, we used
Bonferroni correction for multiple testing. For the primary
hypothesis traits this resulted in a significance level of p,0.0004,
whereas it for follow-up traits resulted in a significance level of
p,0.0001.
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